Home > Oncology > Early-Stage NSCLC: Promising Data for Neoadjuvant Durvalumab With Stereotactic Body Radiotherapy

Early-Stage NSCLC: Promising Data for Neoadjuvant Durvalumab With Stereotactic Body Radiotherapy

Presented By
Dr Nassar Altorki, New York Presbyterian-Weill Cornell Medical Center, New York, USA

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 175
Journal
Physician's Weekly
Conference
ASCO 2021
A recently published phase 2 study in Lancet Oncology showed that the combination of neoadjuvant durvalumab with stereotactic body radiotherapy (SBRT) is safe and grants a nearly 55% major pathologic response rates among patients with early-stage non-small cell lung cancer (NSCLC) [1]. The response rate rose further up to 70% when patients with EGFR mutations were excluded from the analysis. Medicom’s journalist spoke with corresponding author Nassar Altorki, a Professor of Cardiothoracic Surgery and the Director of the Division of Thoracic Surgery at New York Presbyterian-Weill Cornell Medical Center in New York. The results of a single center open-label phase 2 study (NCT02904954) published in


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on